Parabilis now the largest VC-backed biotech IPO
Parabilis Medicines’ $745M IPO redefines biotech funding—now the largest VC-backed debut in history.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Parabilis Medicines has completed its initial public offering (IPO) on NASDAQ, raising $745 million after upsizing its deal. The company’s shares surged 67% on debut, propelling its market capitalization to $3.7 billion—the largest VC-backed biotech IPO to date. Coverage highlights its focus on targeting previously 'undruggable' diseases, positioning it as a leader in high-risk, high-reward drug development.
Financial and biotech media outlets, including Bloomberg, WSJ, and BioSpace, emphasize the IPO’s record-breaking valuation and the broader market signal it sends. The surge follows a trend of high-profile biotech IPOs, though analysts note the optimism is concentrated in companies with reduced development risk. Watch for investor reactions to Parabilis’ pipeline progress and whether its success spurs more VC-backed biotechs to pursue IPOs.
Coverage also suggests scrutiny of whether the market can sustain valuations for early-stage biotech firms beyond the 'derisked' subset.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (88% supported) Updated 134d ago.
Quick answers
What is Parabilis Medicines’ market cap after its IPO?
Parabilis Medicines’ market cap reached $3.7 billion following its first day of trading on NASDAQ.
How much did Parabilis raise in its IPO?
Parabilis raised $745 million after upsizing its initial public offering.
What distinguishes Parabilis from other biotech IPOs?
Parabilis is noted for targeting 'undruggable' diseases and has become the largest VC-backed biotech IPO to date, signaling confidence in its high-risk, high-reward approach.
Coverage (10)
- 'Going for our own moonshot': Parabilis CEO on biotech's record IPO Endpoints News · 136d ago
- Parabilis Medicines Rings the Closing Bell Nasdaq · 136d ago
- Drugmaker Parabilis Soars 67% After $745 Million IPO, Placement Bloomberg.com · 136d ago
- Parabilis soars to $3.7B market cap after first day on NASDAQ FirstWord Pharma · 136d ago
- Parabilis Medicines Shares Rocket Following Record Biotech IPO WSJ · 136d ago
- Parabilis Medicines’ Quest to Drug the Undruggable Picks Up $745M From Upsized IPO MedCity News · 136d ago
- Sky-high Parabilis, Kailera IPOs spur optimism—but only for derisked biotechs BioSpace · 136d ago
- Parabilis Medicines Announces Pricing of Upsized Initial Public Offering Stock Titan · 136d ago
- Parabilis sets a record with a $670M biotech IPO BioPharma Dive · 136d ago
- Parabilis now the largest VC-backed biotech IPO Yahoo Finance · 136d ago
Topics
Related trends
AI infrastructure: The gap between capex and cash generation (CRWV:NASDAQ)
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
Nasdaq climbs and tech shares bounce following a chip selloff while the Dow and S&P 500 drift in mixed trading.
Meta stock pares losses in pre-market trading following yesterday's 7% decline
Meta stock pares pre-market losses following a 7 percent decline, as third-quarter revenue tops estimates and Muse accounts surpass 10 million.
Western Digital Reports Quarterly Earnings Beat
Western Digital reports a quarterly earnings beat driven by AI demand, yet its stock faces volatile market reactions.
Stock futures remain under pressure after worst Nasdaq session since June: Live updates
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Asian Stocks to Slide on Tech Rout, Bonds Rally: Markets Wrap
Asian stocks face slides and bonds rally as global markets grapple with an intense technology sector rout driven by artificial intelligence concerns.